|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||307.15 - 311.11|
|52 Week Range||244.28 - 348.84|
|PE Ratio (TTM)||20.33|
|Earnings Date||Oct 24, 2017 - Oct 30, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||359.00|
Biogen Inc (NASDAQ:BIIB)’s sound earnings growth per share is expected to be a double-digit 43.43% over the next three years. Presently, with an EPS of $16.296, we can expect anRead More...
Four months after losing its longtime chief financial officer to another drugmaker, Biogen has appointed a former Boston Scientific executive to that post. Cambridge-based Biogen (BIIB) said Tuesday that Jeffrey Capello will take over as CFO on Dec. 11. Before that, he founded and ran his own financial advisory firm in Boston, and held CFO roles at Ortho Clinical Diagnostics, Boston Scientific Corp. (BSX) and PerkinElmer (PKI).
Biogen announced today the appointment of Jeffrey D. Capello as Executive Vice President and Chief Financial Officer effective as of December 11, 2017.
Biogen Inc. announced today that it will present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference. The webcast will be live on Wednesday, November 29, 2017 at 2:20 p.m.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $763 million.
Ever since its cholesterol-fighting drug Lipitor lost the crux of its patent protection back in 2011, Pfizer Inc. (NYSE:PFE) investors have approached PFE stock with caution. Early this week, Purkiss made a point of saying sales of Ibrance is being underestimated, suggesting that rather than achieving just a little less than $7 billion in revenue in 2023, it could actually produce nearly $13-billion worth of business that year as its approved uses were expanded and caregivers saw its efficacy.
Cohen's best-performing stocks include Biogen Inc (NASDAQ: BIIB ), Magna International Inc. (USA) (NYSE: MGA ) and Gap Inc (NYSE: GPS ). Billions to Billions If you haven't heard of Billionaire Steven ...
Philanthropists such as Bill Gates are investing millions in Alzheimer's research. But a new study proposes that the U.S. healthcare system wouldn't have the bandwidth required to treat the influx of patients expected over the next two decades.
Everyone has heard the talk. Pfizer (PFE) is getting ready to make a deal. the skinny on Wall Street is that the U.S. pharmaceutical giant has its eyes set on rival Bristol-Myers Squibb (BMY) and its immuno-oncology ...
Biogen announced today the appointment of Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation.
Research Desk Line-up: Seattle Genetics Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 2, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Biogen Inc. (NASDAQ: BIIB ...
Biogen will present new data from the long-term extension of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment for Alzheimer’s disease, at the Clinical Trials on Alzheimer’s Disease meeting, Boston, November 1 – 4.
Biogen and Ionis Pharmaceuticals, Inc. announced that the end of study results from ENDEAR, the Phase 3 study of SPINRAZA® for the treatment of spinal muscular atrophy , were published today in The New England Journal of Medicine.
Biogen Inc. announced today that it will present detailed data from a recently conducted analysis of the long-term extension of its ongoing Phase 1b study of aducanumab at the 10th Clinical Trials on Alzheimer’s Disease Conference meeting in Boston.
Biogen and Ionis have been awarded the prestigious 2017 Prix Galien USA Award for Best Biotechnology Product for SPINRAZA® . The Prix Galien USA Award recognizes extraordinary achievement in scientific innovation that improves the state of human health.
Research Desk Line-up: Biogen Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Viking Therapeutics, ...
Biogen announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on therapy in people with relapsing multiple sclerosis .